ClinicalTrials.gg
Status unknownNCT05018013Updated Nov 12, 2021

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

A Phase 2 interventional study of Ammoxetine hydrochloride enteric-coated tablets and Duloxetine hydrochloride enteric-coated capsules in Major Depressive Disorder (MDD), sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-11-12.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Depressive Disorder, Major with a site in China — 74 open to participants now, 77 under way, 5 of them phase 3. Depressive Disorder, Major · China.

Planned enrollment
49th of 173
240 · median 120
Started
2021
with 15 others
Phase 2
19 of 206
3 open now
Registered
88th of 206
by date

Among the 206 studies in Depressive Disorder, Major with a site in China, this one is the 49th largest by planned enrollment of the 173 interventional ones that give a count, is one of 16 that started in 2021, is one of 19 in phase 2, and was the 88th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

74 of the 206 studies in Depressive Disorder, Major with a site in China are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Depressive Disorder, Major with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.

Read the detailed description

In this study, a randomized, double-blind, duloxetine hydrochloride enteric coated capsule positive and placebo-controlled multicenter study was used to evaluate the efficacy and safety of different doses of amxetine hydrochloride enteric coated tablets in the treatment of depression.

03

Conditions studied

  • Major Depressive Disorder (MDD)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Subjects aged 18 and 65 years (inclusive), no gender limitation;
    1. Subject has recurrent Major Depressive Disorder (MDD) as the primary diagnosis according to (DSM-5, 5th Edition), single episode or recurrent episodes (DSM-IV-TR criteria, classification code 296.2/296.3), without psychotic symptoms;
    1. Subjects with a Montgomery-Asberg Depression Rating Scale (MADRS) score ≥ 26 and subjects with Clinical Global Impression Scale Disease Severity CGI-S severity score ≥ 4 at screening and baseline;
    1. For male or female with fertility: must agree to use effective method during the study and within 1 month after the end of the trial;
    1. Be able to read and understand the content of the and voluntarily sign the informed consent.

Exclusion criteria

Exclusion Criteria:

    1. Subjects with ≥ 25% reduction in MADRS score in the baseline period compared to the screening period;
    1. Subjects meet diagnostic criteria for other mental disorders (schizophrenia spectrum and other psychiatric disorders, bipolar and related disorders, anxiety disorders, obsessive-compulsive and related disorders, somatic symptoms and related disorders, etc.);
    1. Subjects are diagnosed as DSM-5 drug use disorder;
    1. depression (subjects who had previously used two different mechanisms of antidepressants and failed after receiving adequate treatment (at least 8 weeks);
    1. Organic mental disorders, such as depression caused by hypothyroidism;
    1. Depression caused by psychoactive substances or non-addictive substances;
    1. Subjects with other diseases or other types of mental disorders with depressive symptoms;
    1. Subjects assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) and those judged by the investigator to be at risk for suicide, or to have engaged in suicidal behaviour within 6 months prior to screening;
    1. Allergic constitution (e.g. allergic to two or more drugs or to serotonin norepinephrine reuptake inhibitors (SNRIs));
  • 10.Previous history of malignant tumor;
  • 11.Previous history of elevated intraocular pressure or narrow angle glaucoma;
  • 12.Subjects suffered from other serious physical diseases, such as uncontrolled hypertension or unstable cardiovascular disease, serious liver disease, kidney disease, blood disease, endocrine disease, neurological disease, etc;
  • 13.Subjects with diseases that interfere with the absorption of oral medications, such as active bowel disease, partial or complete intestinal obstruction, chronic diarrhea, etc;
  • 14.Subjects who have used drugs or foods that alter the activity of liver enzymes (CYP2C19 and ) such as dexamethasone, rifampicin, omeprazole, grapefruit, etc., within 4 weeks prior to screening;
  • 15.12-lead system showed degree II or III atrioventricular block, long syndrome or QTc > 450 ms (male) / 470 ms (female) at screening;
  • 16.Subjects discontinued use of a combination of drugs that prolong the QT interval prior to randomization, or drugs that can cause prolongation of the QT and may induce TdP for less than 5 half-lives of the drugs;
  • 17.In screening period, subjects with or AST 1.5 times higher than the upper limit of laboratory normal value; creatinine 1.1 times higher than the value; and abnormalities in 2 or more of the 5 indicators of thyroid function (TSH, FT3, FT4, TT3 or TT4 0.9 times below the lower limit of normal value or 1.1 times above the upper limit of normal value);
  • 18.Subjects have used monoamine oxidase inhibitors within 2 weeks before randomization;
  • 19.Subjects discontinuing antipsychotics, antidepressants or mood stabilizers for less than 5 half-lives of the drug before randomization;
  • 20.Subjects who are using long half-life drugs (such as fluoxetine, long-acting antipsychotics, etc.);
  • 21.Subjects who have received electroconvulsive therapy (ECT), systematic psychotherapy (interpersonal relationship therapy, dynamic therapy, cognitive behavior therapy, etc.), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), phototherapy, etc. within 3 months before screening, or subjects who, in the judgment of the investigator, are currently in need of such treatment;
  • 22.Female subjects who are breastfeeding or have a positive pregnancy test during the screening period or during the study;
  • 23.Alcohol or drug dependence within 3 months before screening;
  • 24.Subjects who have participated in other clinical trials within 3 months before screening and are taking the test drug;
  • 25.Subjects who, in the opinion of the investigator, have any other condition that makes them unsuitable for participation in this trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
240 participants (estimated)

Study arms

  • Active comparator
    Duloxetine group

    The eligible subjects will receive duloxetine hydrochloride enteric-coated capsules plus placebo to Ammoxetine.

    Drug: Duloxetine hydrochloride enteric-coated capsules · Drug: Placebo to Ammoxetine

  • Placebo comparator
    Placebo group

    The eligible subjects will receive placebo to Ammoxetine and placebo to Duloxetine.

    Drug: Placebo to Ammoxetine · Drug: Placebo to Duloxetine

  • Experimental
    Ammoxetine group-cohort 1

    The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.

    Drug: Ammoxetine hydrochloride enteric-coated tablets · Drug: Placebo to Duloxetine

  • Experimental
    Ammoxetine group-cohort 2

    The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.

    Drug: Ammoxetine hydrochloride enteric-coated tablets · Drug: Placebo to Duloxetine

  • Experimental
    Ammoxetine group-cohort 3

    The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.

    Drug: Ammoxetine hydrochloride enteric-coated tablets · Drug: Placebo to Duloxetine

  • Experimental
    Ammoxetine group-cohort 4

    The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.

    Drug: Ammoxetine hydrochloride enteric-coated tablets · Drug: Placebo to Duloxetine

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in Montgomery Asperger Depression Scale (MADRS) score at the end of treatment (week 6)

    The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement. Change = (Week 6 post-dose score - baseline week 0 score). at the end of treatment (week 6)

    Time frame: Baseline and week 6

Secondary outcomes

  1. Change from baseline in Hamilton Depression Scale (HAMD-17) at week 1, 2, 4, 6

    The HAMD-17 is a 17-item, clinician-rated scale that assesses depressive symptoms. The HAMD-17 consists of 17 symptoms, each of which is rated from 0 to 2 or 0 to 4, where 0 is none/absent. The HAMD-17 total score is calculated as the sum of the 17 individual symptom scores; the total score can range from 0 to 52. Higher HAMD-17 scores indicate more severe depression. Change = (Week 1, 2, 4 and 6 post-dose score - baseline week 0 score).

    Time frame: Baseline, week 1, 2, 4 and 6

  2. Change from baseline in Hamilton Anxiety Inventory (HAMA) scores at week 1, 2, 4, 6

    The HAMA is used as a rating measure of anxiety severity. The scale consists of 14 items. Each item is rated on a scale of 0 to 4. The HAMA total score is the sum of the 14 items and the score ranges from 0 to 56, 0 is considered the best outcome. Change = (Week 1, 2, 4 and 6 post-dose score - baseline week 0 score).

    Time frame: Baseline, week 1, 2, 4 and 6

  3. Change from baseline in CGI-S score at week 1, 2, 4, 6,7

    The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment. The CGI-S will provide an overall clinician-determined summary measure that takes into account all available information including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. Change = (Week 1, 2, 4, 6 and 7 post-dose score - baseline week 0 score).

    Time frame: Baseline, week 1, 2, 4, 6 and 7

  4. The percentage of subjects with a MARDS score reduction ≥ 25%

    The score reduction rate is defined as (screening period MARDS scale score - post-dose MARDS scale score)/screening period MARDS scale score x 100%.

    Time frame: Week 1 and 2

  5. Incidence of adverse events (AE)

    The AEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0.

    Time frame: Throughout the study period,an average of 18 months

  6. Change from baseline in MADRS score at week 1, 2, 4

    Change = (Week 1, 2 and 4 post-dose score - baseline week 0 score).

    Time frame: baseline, week 1, 2 and 4

07

Study locations

1 of 1 sites recruiting
  • Shanghai Mental Health Center
    Shanghai, Shanghai 200030, China
    Recruiting
    • Li Huafang, Ph.D · Contact86-021-34773128
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Aug 2022, 11 months after the start.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's planned 11 months is below that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2021
First posted
Aug 24, 2021
StartActual
Aug 21, 2021
Primary completionEst.
Aug 1, 2022
CompletionEst.
Dec 30, 2022
Last update
Nov 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05018013
Responsible party
Sponsor
First posted
Aug 24, 2021
Start date
Aug 21, 2021
Primary completion
Aug 1, 2022 (estimated)
Completion
Dec 30, 2022 (estimated)
Last update
Nov 12, 2021

Study contacts

Li Yang, MA
Contact
lcliyang@mail.ecspc.com
+86-13321898532 ext. +86-021606739
Huang Yanli, MD
study director · CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd
Li Huafang, Ph.D
study chair · Shanghai Mental Health Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ammoxetine

Start the discussion